TY  - GEN
AU  - Fowler,Nathan
AU  - Kahl,Brad S
AU  - Lee,Peter
AU  - Matous,Jeffrey V
AU  - Cashen,Amanda F
AU  - Jacobs,Samuel A
AU  - Letzer,Jeffrey
AU  - Amin,Bipinkumar
AU  - Williams,Michael E
AU  - Smith,Sonali
AU  - Saleh,Alfred
AU  - Rosen,Peter
AU  - Shi,Hongliang
AU  - Parasuraman,Sudha
AU  - Cheson,Bruce D
TI  - Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study
SN  - 1527-7755
PY  - 2011///1024
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bendamustine Hydrochloride
KW  - Boronic Acids
KW  - Bortezomib
KW  - Dose-Response Relationship, Drug
KW  - Drug Resistance, Neoplasm
KW  - drug effects
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Nitrogen Mustard Compounds
KW  - Pyrazines
KW  - Rituximab
KW  - Salvage Therapy
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2010.32.1844
ER  -